{"id":"W2150866539","doi":"10.1634/theoncologist.2014-0028","title":"An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Internal medicine; FOLFOX; Bevacizumab; Oncology; Colorectal cancer; Neutropenia; Progression-free survival; Oxaliplatin; Regimen; Phases of clinical research; Adverse effect; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001440728,0.0001701566,0.0002915426,0.00001118159,0.0005436042,0.0000367558,0.0005125443,0.00004846371,0.00002700842],"category_scores_gemma":[0.0001343429,0.00008301771,0.00003593594,0.00008417764,0.0003107069,0.00000576866,0.0001679928,0.00005872687,3.617262e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000218601,"about_ca_system_score_gemma":0.0001675649,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002821358,"about_ca_topic_score_gemma":0.001028875,"domain_scores_codex":[0.9988203,0.0002845005,0.0002526568,0.0003148355,0.0001354241,0.0001922711],"domain_scores_gemma":[0.9989421,0.0002374948,0.0002363863,0.0003948295,0.0001451611,0.00004403602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1015342,0.01357453,0.002017013,0.00004485235,0.001665022,0.000001957034,0.002319655,0.002573148,0.4428879,0.0007552431,0.001028194,0.4315983],"study_design_scores_gemma":[0.1361731,0.7009736,0.01056701,0.00006499748,0.001043546,0.00001995165,0.002209765,0.01573166,0.1138189,0.0004135247,0.0181558,0.0008281881],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951223,0.0008143944,0.0008180404,0.0007474321,0.00006933182,0.002221864,0.00004806477,0.000007288996,0.0001512702],"genre_scores_gemma":[0.9979634,0.0003108512,0.0004389385,0.0004626638,0.0001198137,0.0004701735,0.00004191067,0.00002487762,0.0001673446],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.687399,"threshold_uncertainty_score":0.4181019,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07877267716082854,"score_gpt":0.4312235175892444,"score_spread":0.3524508404284158,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}